CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 78 enrolled
Drug / intervention
Fluzone® 2012-2013 Formula NDC No 498281-012-50biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02134184
NCT02134184Phase 4Completed
CompareCT.gov

The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses

Stanford University·interventional·Posted May 9, 2014·Updated Apr 19, 2023

In Brief

A Phase 4 clinical trial evaluating Fluzone® 2012-2013 Formula NDC No 498281-012-50 for Cytomegalovirus Infections and Influenza. Completed, enrolled 78 participants across 1 site.

Detailed Summary

In this study we are trying to understand whether previous infection with a particular virus, namely cytomegalovirus (CMV), influences the ability of the immune system to respond to new infections or vaccinations with age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infections, Influenza
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 9, 2014
Enrollment StartOct 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.1 years ago

Interventions

Fluzone® 2012-2013 Formula NDC No 498281-012-50biological

This vaccine is given intramuscularly